Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.

Shah R, Buchmeier EL, Kopp HG, Griesinger F, Reck M, Christoph DC, Kuon J, Frost N, Grohé C, Faehling M, Saalfeld FC, Hoffknecht P, Luan J, Roeper J, Chesi P, Kimmich M, Olchers T, Klotz LV, Chung I, Thomas M, Christopoulos P

Open source

DOI
10.1016/j.cllc.2026.06.001
Published
2026 Jul
Container
Clinical lung cancer
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2026.06.001,
  title = {Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.},
  author = {Shah R and Buchmeier EL and Kopp HG and Griesinger F and Reck M and Christoph DC and Kuon J and Frost N and Grohé C and Faehling M and Saalfeld FC and Hoffknecht P and Luan J and Roeper J and Chesi P and Kimmich M and Olchers T and Klotz LV and Chung I and Thomas M and Christopoulos P},
  year = {2026},
  journal = {Clinical lung cancer},
  doi = {10.1016/j.cllc.2026.06.001},
  url = {https://doi.org/10.1016/j.cllc.2026.06.001}
}

RIS

TY  - JOUR
TI  - Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.
AU  - Shah R
AU  - Buchmeier EL
AU  - Kopp HG
AU  - Griesinger F
AU  - Reck M
AU  - Christoph DC
AU  - Kuon J
AU  - Frost N
AU  - Grohé C
AU  - Faehling M
AU  - Saalfeld FC
AU  - Hoffknecht P
AU  - Luan J
AU  - Roeper J
AU  - Chesi P
AU  - Kimmich M
AU  - Olchers T
AU  - Klotz LV
AU  - Chung I
AU  - Thomas M
AU  - Christopoulos P
PY  - 2026
JO  - Clinical lung cancer
DO  - 10.1016/j.cllc.2026.06.001
UR  - https://doi.org/10.1016/j.cllc.2026.06.001
ER  - 

APA

R, S., EL, B., HG, K., F, G., M, R., DC, C., J, K., N, F., C, G., M, F., FC, S., P, H., J, L., J, R., P, C., M, K., T, O., LV, K., I, C., M, T., & P, C. (2026). Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.. Clinical lung cancer. https://doi.org/10.1016/j.cllc.2026.06.001

Source records